A recent study indicates that liraglutide, a GLP-1 drug from Novo Nordisk used for diabetes and obesity, may slow the progression of Alzheimer's disease. Conducted by researchers at Imperial College London, the Phase 2 trial involved over 200 patients who received either liraglutide or a placebo, revealing an 18% slower cognitive decline and nearly 50% less brain shrinkage in those treated with the drug. Although the primary endpoint regarding brain sugar metabolism was not met, the findings suggest that GLP-1 medications might offer neuroprotective benefits. Presented at the Alzheimer’s Association International Conference, this research adds to the growing interest in repurposing diabetes medications for neurological conditions. Further large-scale trials are underway to confirm these results and explore the potential of GLP-1 drugs in treating Alzheimer’s.